News | January 29, 2026
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Subscribe To Our Newsletter & Stay Updated
